Enlighten Medical Limited

Enlight Medical was founded in Boston, Massachusetts, the United States. It is a stable and rapidly growing global medical technology company, focusing on interventional medical devices for structural heart diseases and intravascular diseases, as well as neuromodulation products. The company has established R&D centers or production bases in Boston, San Francisco, Shanghai, Beijing and Shenzhen, and all of its production workshops comply with GMP standards. Enlight Medical is developing transcatheter mitral valve repair and replacement devices, thoracic endovascular stent graft to treat aortic dissection, and innovative peripheral stents to treat PAD, deep brain stimulation (DBS) and spinal cord stimulation (SCS) devices, and both invasive and non-invasive BCIs to help replace, restore, or improve human functions. Enlight Medical has partnered with Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, to accelerates commercial availability of Seer’s Proteograph Product Suite to the rapidly expanding Chinese life sciences and clinical markets.